1t2f

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1t2f.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1t2f.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1t2f| PDB=1t2f | SCENE= }}
{{STRUCTURE_1t2f| PDB=1t2f | SCENE= }}
-
'''Human B lactate dehydrogenase complexed with NAD+ and 4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid'''
+
===Human B lactate dehydrogenase complexed with NAD+ and 4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid===
-
==Overview==
+
<!--
-
Plasmodium falciparum, the causative agent of malaria, relies extensively on glycolysis coupled with homolactic fermentation during its blood-borne stages for energy production. Selective inhibitors of the parasite lactate dehydrogenase (LDH), central to NAD(+) regeneration, therefore potentially provide a route to new antimalarial drugs directed against a novel molecular target. A series of heterocyclic, azole-based compounds are described that preferentially inhibit P. falciparum LDH at sub-micromolar concentrations, typically at concentrations about 100-fold lower than required for human lactate dehydrogenase inhibition. Crystal structures show these competitive inhibitors form a network of interactions with amino acids within the active site of the enzyme, stacking alongside the nicotinamide ring of the NAD(+) cofactor. These compounds display modest activity against parasitized erythrocytes, including parasite strains with known resistance to existing anti-malarials and against Plasmodium berghei in BALB/c mice. Initial toxicity data suggest the azole derivatives have generally low cytotoxicity, and preliminary pharmoco-kinetic data show favorable bioavailability and circulation times. These encouraging results suggest that further enhancement of these structures may yield candidates suitable for consideration as new therapeutics for the treatment of malaria. In combination these studies also provide strong support for the validity of targeting the Plasmodium glycolytic pathway and, in particular, LDH in the search for novel anti-malarials.
+
The line below this paragraph, {{ABSTRACT_PUBMED_15117937}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 15117937 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_15117937}}
==Disease==
==Disease==
Line 49: Line 53:
[[Category: Winter, V J.]]
[[Category: Winter, V J.]]
[[Category: Protein-ligand complex]]
[[Category: Protein-ligand complex]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 09:25:58 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 23:24:08 2008''

Revision as of 20:24, 28 July 2008

Image:1t2f.png

Template:STRUCTURE 1t2f

Contents

Human B lactate dehydrogenase complexed with NAD+ and 4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid

Template:ABSTRACT PUBMED 15117937

Disease

Known disease associated with this structure: Lactate dehydrogenase-B deficiency OMIM:[150100]

About this Structure

1T2F is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity., Cameron A, Read J, Tranter R, Winter VJ, Sessions RB, Brady RL, Vivas L, Easton A, Kendrick H, Croft SL, Barros D, Lavandera JL, Martin JJ, Risco F, Garcia-Ochoa S, Gamo FJ, Sanz L, Leon L, Ruiz JR, Gabarro R, Mallo A, Gomez de las Heras F, J Biol Chem. 2004 Jul 23;279(30):31429-39. Epub 2004 Apr 26. PMID:15117937

Page seeded by OCA on Mon Jul 28 23:24:08 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1t2f"
Personal tools